Revolution Medicines Stock

revolutionmedicines.comHealthcare / BioTech & PharmaFounded: 2014Funding to Date: $226MM

REVOLUTION Medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients.

Register for Details

For more details on financing and valuation for Revolution Medicines, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Revolution Medicines.

Register Today

Team

Management Team

Mark Goldsmith Ph.D
President, Chief Executive Officer and Board Member
Martin Burke MD
Scientific Advisory Board Chairman & Co-Founder
Kevan Shokat Ph.D
Co-Founder & Chief Advisory Board Member
Steve Kelsey MD
President, Research & Development
Margaret Horn JD
Chief Operating Officer
Michael Fischbach Ph.D
Co-Founder & Scientific Advisory Board Member

Board Members

Alexis Borisy
Third Rock Ventures
Kevan Shokat Ph.D
Michael Fischbach Ph.D
Barbara Weber MD
Third Rock Ventures
Martin Burke MD
Vincent Miller MD
Elizabeth Anderson
Laurence Lasky Ph.D
The Column Group
Thilo Schroeder Ph.D
Nextech Invest

Other companies like Revolution Medicines in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Revolution Medicines Announces Pricing of Initial Public Offering
REDWOOD CITY, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD) today announced the pricing of its initial public...
Xconomy: Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
The RAS family of proteins is one of the hottest targets in cancer research despite being one of the hardest for drug hunters to hit. Revolution Medicines
Revolution Medicines Closes $100M Financing | FinSMEs
Revolution Medicines, Inc., a Redwood City, Calif.-based clinical-stage leader in the discovery and development of novel small molecule inhibitors of frontier oncology targets within notorious pathways, closed a $100m Series C equity financing
Updated on: Sep 27, 2023